Renaissance Technologies LLC Has $1.56 Million Stock Holdings in OnKure Therapeutics, Inc. $OKUR

Renaissance Technologies LLC increased its stake in shares of OnKure Therapeutics, Inc. (NASDAQ:OKUR) by 52.5% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 377,250 shares of the company’s stock after buying an additional 129,900 shares during the period. Renaissance Technologies LLC owned 0.93% of OnKure Therapeutics worth $1,562,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. ADAR1 Capital Management LLC bought a new position in OnKure Therapeutics in the 4th quarter valued at about $2,941,000. Shay Capital LLC boosted its holdings in shares of OnKure Therapeutics by 17.4% during the third quarter. Shay Capital LLC now owns 917,934 shares of the company’s stock worth $2,524,000 after acquiring an additional 135,888 shares during the period. Prosight Management LP grew its position in shares of OnKure Therapeutics by 204.9% in the fourth quarter. Prosight Management LP now owns 816,909 shares of the company’s stock valued at $2,369,000 after purchasing an additional 548,950 shares during the last quarter. Rosalind Advisors Inc. acquired a new position in shares of OnKure Therapeutics in the fourth quarter valued at approximately $2,118,000. Finally, Kotler Kevin bought a new position in shares of OnKure Therapeutics during the fourth quarter worth approximately $573,000. Institutional investors and hedge funds own 90.98% of the company’s stock.

Analyst Upgrades and Downgrades

OKUR has been the subject of several recent research reports. HC Wainwright reduced their price target on OnKure Therapeutics to $21.00 and set a “buy” rating for the company in a research note on Monday, July 20th. Weiss Ratings cut OnKure Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, July 28th. Wall Street Zen raised OnKure Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, June 6th. Finally, JonesTrading cut shares of OnKure Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 7th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, OnKure Therapeutics presently has a consensus rating of “Hold” and an average target price of $21.00.

OnKure Therapeutics Trading Down 3.9%

NASDAQ OKUR opened at $3.93 on Thursday. OnKure Therapeutics, Inc. has a 1-year low of $2.18 and a 1-year high of $5.38. The company has a 50 day moving average of $4.25 and a 200-day moving average of $3.86. The company has a market cap of $158.77 million, a price-to-earnings ratio of -1.12 and a beta of 0.29.

OnKure Therapeutics (NASDAQ:OKUR) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.23. On average, equities research analysts forecast that OnKure Therapeutics, Inc. will post -2.57 earnings per share for the current year.

About OnKure Therapeutics

OnKure Therapeutics, Inc (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.